Alvotech is a global biotech company that develops and manufactures biosimilar medicines—lower-cost versions of approved biologic drugs—for commercialization across multiple geographic markets including Europe, North America, Asia, and Japan. The company generates revenue through two primary streams: direct product sales to commercial partners at negotiated prices, and long-term licensing agreements that grant partners exclusive territorial marketing rights in exchange for upfront payments, development and regulatory milestone payments, and ongoing royalties on net sales. Alvotech operates a partnership-driven commercialization model, relying on established pharmaceutical companies to market and sell its biosimilar products while the company maintains manufacturing and development capabilities across its operations in Iceland, Switzerland, Germany, Sweden, the United States, India, and other locations.